Protagenic Therapeutics (PTIX) chair buys 685 shares at $0.22

Rhea-AI Filing Summary

Protagenic Therapeutics, Inc. director and executive chair Armen Garo reported purchasing 685 shares of common stock on 2026-08-06 at $0.22 per share in an open-market or private transaction. Following this transaction, his directly owned holdings total 31,979 common shares.

Insider Trade Summary

Net Buyer: 685 shares

Net Buy 1 txn

Insider ARMEN GARO H

Role EXEC. CHAIR & PRINCIPAL OFF

Bought 685 shs ($150.70)

Type	Security	Shares	Price	Value
Purchase	COMMON STOCK	685	$0.22	$150.70

Holdings After Transaction: COMMON STOCK — 31,979 shares (Direct)

Key Figures

Shares purchased: 685 shares Purchase price: $0.22 per share Shares owned after transaction: 31,979 shares +1 more

4 metrics

Shares purchased 685 shares Common stock purchase on 2026-08-06

Purchase price $0.22 per share Open-market or private transaction price

Shares owned after transaction 31,979 shares Directly owned common stock following the purchase

Net buy shares 685 shares Net buy direction in transaction summary

Key Terms

open market or private transaction, Rule 10b5-1

2 terms

open market or private transaction financial

"transaction code description notes a Purchase in open market or private transaction"

Rule 10b5-1 regulatory

"aff_10b5_one field reflects the Rule 10b5-1 trading plan checkbox status"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/10/2026 - 10:17 AM Accepted by SEC EDGAR 08/10/2026 - 10:17 AM Learn about SEC filing dates

FAQ

What insider transaction did PTIX report for Armen Garo?

Armen Garo reported buying 685 shares of Protagenic Therapeutics common stock on 2026-08-06 at $0.22 per share, increasing his directly held position to 31,979 shares.

At what price did the PTIX executive chair buy shares?

The PTIX executive chair bought shares at $0.22 per share. The transaction involved 685 common shares in an open-market or private transaction, as disclosed in the Form 4 filing.

How many PTIX shares does Armen Garo hold after this trade?

After the reported purchase, Armen Garo holds 31,979 shares of PTIX common stock directly. This reflects the addition of 685 shares acquired on 2026-08-06 at $0.22 per share.

Was the PTIX insider trade under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not affirmed, indicating the reported 685-share purchase at $0.22 per share was not disclosed as executed under a pre-arranged trading plan.

What type of transaction was reported in the PTIX Form 4?

The PTIX Form 4 reports a purchase of common stock, coded “P” for “Purchase in open market or private transaction,” covering 685 shares at $0.22 per share on 2026-08-06.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ARMEN GARO H

(Last) (First) (Middle)

C/O AGENUS INC.

3 FORBES ROAD

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagenic Therapeutics, Inc.\new [ PTIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXEC. CHAIR & PRINCIPAL OFF

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	08/06/2026		P		685	A	$0.22	31,979	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Garo H. Armen	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)